医学
咪唑安定
麻醉
癫痫持续状态
不利影响
左乙拉西坦
耐火材料(行星科学)
重症监护室
持续输注
回顾性队列研究
镇静
病历
重症监护
癫痫
临床试验
重症监护医学
抗惊厥药
苯巴比妥
套管
作者
Alessandro Orsini,Lorenza Marini,Luca Bergonzini,Francesco D'Angelo,Silvia Lelli,Thomas Foiadelli,Eugenia Spreafico,Viola Santi,Elisabetta Mencaroni,Alberto Verrotti,Alessandro Ferretti,Pasquale Parisi,R. Morganti,Brita De Lorenzo,Beate Kuppers,Alice BONUCCELLI,Carla Battisti,Diego Peroni,Duccio Maria Cordelli
出处
期刊:PubMed
[National Institutes of Health]
日期:2026-03-06
摘要
Seizures, when prolonged or repeated, leading to status epilepticus (SE), represent a medical emergency, requiring prompt treatment. In these conditions, the use of continuous midazolam (MDZ) infusion is often reserved for established or refractory SE and considered an anesthesiologic treatment, while evidence on its early use in non-intensive settings is still limited. To verify this approach in daily practice, we retrospectively collected data on about 42 episodes of pediatric SE or acute repetitive seizures (ARSs), treated with continuous MDZ infusion in non-intensive setting. Collected data include demographical information, previous history of epilepsy, instrumental examinations (electroencephalography [EEG] and brain magnetic resonance imaging [MRI]), comorbidities, anti-seizure medications (ASMs), information about the event, other treatments (first- and second-line), information about MDZ infusion, and need for other third-line treatment and/or intensive care unit (ICU) transfer. Infusion durations and rates varied widely, but in most cases (38/42) low dose (<.23 mg/kg/h) were employed. The treatment was effective in 84.2% of cases, achieving both clinical and EEG response. No adverse events (AEs) were reported. The need for a second-line treatment (particularly levetiracetam [LEV] and phenobarbital [PB]) was associated with a worse outcome. Another third-line treatment was needed in 9.5% of cases. Patients (21.4%) were transferred to ICU; a higher risk of ICU admission was reported in patients with precipitating factors (infection, surgery, hypertension and suboptimal anti-seizure medication [ASM] serum levels), and those receiving MDZ infusion at higher rates and/or co-treated with PB. Overall, our study suggests that low-dose continuous MDZ infusion is an effective and safe strategy for treatment of pediatric SE and ARSs in non-intensive settings.